• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cybin, Field Trip Health Among Top Psychedelic Movers Of Today

    8/9/22 4:35:41 PM ET
    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email

     

    GAINERS:

    • Cybin (AMEX:CYBN) shares closed up 10.35% at $0.79
    • Field Trip Health (NASDAQ:FTRP) shares closed up 6.25% at $0.85
    • Allied (OTC:ALID) shares closed up 1.06% at $0.47
    •  

    LOSERS:

    • Numinus Wellness (OTC:NUMIF) shares closed down 5.09% at $0.23
    • Compass Pathways (NASDAQ:CMPS) shares closed down 3.56% at $18.94
    • GH Research (NASDAQ:GHRS) shares closed down 3.50% at $11.58
    • Revive Therapeutics (OTC:RVVTF) shares closed down 2.80% at $0.35
    • Mind Medicine (NASDAQ:MNMD) shares closed down 1.68% at $0.58
    • Seelos Therapeutics (NASDAQ:SEEL) shares closed down 1.16% at $0.89
    • ATAI Life Sciences (NASDAQ:ATAI) shares closed down 0.45% at $4.41
    • Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $0.75

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI
    $CMPS
    $CYBN
    $FTRP

    CompanyDatePrice TargetRatingAnalyst
    AtaiBeckley Inc.
    $ATAI
    1/20/2026$11.00Buy
    Guggenheim
    COMPASS Pathways Plc
    $CMPS
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    Mind Medicine (MindMed) Inc.
    $MNMD
    10/13/2025$28.00Buy
    Needham
    GH Research PLC
    $GHRS
    10/13/2025$19.00Buy
    Needham
    AtaiBeckley Inc.
    $ATAI
    10/13/2025$12.00Buy
    Needham
    Mind Medicine (MindMed) Inc.
    $MNMD
    8/4/2025$25.00Outperform
    Oppenheimer
    AtaiBeckley Inc.
    $ATAI
    7/29/2025$14.00Outperform
    Oppenheimer
    COMPASS Pathways Plc
    $CMPS
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

    Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for Q2 2026BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depressionVirtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments,

    3/3/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

    2/27/26 11:44:00 AM ET
    $ATAI
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

    2/26/26 12:07:00 PM ET
    $ANRO
    $AXSM
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 16,181 units of Ordinary Shares, decreasing direct ownership by 7% to 205,121 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    2/3/26 5:19:56 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/29/25 5:00:03 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/29/25 5:00:06 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on AtaiBeckley with a new price target

    Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00

    1/20/26 9:22:21 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COMPASS Pathways upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00

    12/10/25 8:10:44 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on MindMed with a new price target

    Needham initiated coverage of MindMed with a rating of Buy and set a new price target of $28.00

    10/13/25 8:54:29 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    SEC Filings

    View All

    COMPASS Pathways Plc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    2/19/26 8:50:58 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by COMPASS Pathways Plc

    424B5 - COMPASS Pathways plc (0001816590) (Filer)

    2/19/26 8:49:57 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by COMPASS Pathways Plc

    424B5 - COMPASS Pathways plc (0001816590) (Filer)

    2/17/26 4:08:59 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Leadership Updates

    Live Leadership Updates

    View All

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

    EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges' g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behavio

    2/26/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care